Vermillion Regains Nasdaq Market Value Compliance; Bid Price Still Low | GenomeWeb
NEW YORK (GenomeWeb News) - Vermillion said yesterday that it has regained compliance for listing on the Nasdaq Stock Market by retaining a market value of $35 million for a period of ten consecutive business days.
 
In August, Nasdaq notified the company, which was called Ciphergen at the time, that it was out of compliance with Nasdaq Marketplace Rule 4310(c)(3) due to insufficient market value.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.